ofloxacin has been researched along with novobiocin in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (10.00) | 18.7374 |
| 1990's | 5 (25.00) | 18.2507 |
| 2000's | 6 (30.00) | 29.6817 |
| 2010's | 7 (35.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aubry, A; Cambau, E; Jarlier, V; Matrat, S | 1 |
| Chen, T; Khalil, H; Riffon, R; Wang, R; Wang, Z | 1 |
| Long, F; Rouquette-Loughlin, C; Shafer, WM; Yu, EW | 1 |
| Hanaki, H; Maseda, H; Nakae, T; Sugimura, M | 1 |
| Banères-Roquet, F; Gualtieri, M; Leonetti, JP; Pugnière, M; Villain-Guillot, P | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Babu, KS; Jeankumar, VU; Reddy, KI; Renuka, J; Shravan, M; Sridevi, JP; Srihari, K; Sriram, D; Yogeeswari, P | 1 |
| Babu, KS; Chuppala, A; Jeankumar, VU; Reddy, KI; Renuka, J; Sree, KS; Sridevi, JP; Srihari, K; Sriram, D; Yogeeswari, P | 1 |
| Renuka, J; Samala, G; Saxena, S; Sridevi, JP; Sriram, D; Yogeeswari, P | 1 |
| Janupally, R; Jeankumar, VU; Reshma, RS; Saxena, S; Sriram, D; Vats, R; Yogeeswari, P | 1 |
| Chaudhari, K; Jain, P; Patel, HM; Surana, S | 1 |
| Howard, BM; Lewin, CS; Smith, JT | 1 |
| Gocke, E | 1 |
| Bia, FJ; Divo, AA; Patton, CL; Sartorelli, AC | 1 |
| Grosse, F; Hussy, P; Maass, G; Schomburg, U; Tümmler, B | 1 |
| Fraimow, HS; French, P; Venuti, E | 1 |
| Howard, BM; Pinney, RJ; Smith, JT | 1 |
| Bernard, FX; Bisch, D; Blanche, F; Cameron, B; Crouzet, J; Ferrero, L; Goniot, A; Lecoq, C; Manse, B; Maton, L; Ratet, N | 1 |
| Bedoui, A; Chekir-Ghedira, L; Cheraif, I; Dhaouifi, Z; Ghedira, K; Kalboussi, Z; Lahmar, A; Mokdad-Bzeouich, I | 1 |
1 review(s) available for ofloxacin and novobiocin
| Article | Year |
|---|---|
Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.
Topics: Antitubercular Agents; Clinical Trials as Topic; DNA Gyrase; Drug Discovery; Humans; Mycobacterium tuberculosis; Topoisomerase II Inhibitors | 2016 |
19 other study(ies) available for ofloxacin and novobiocin
| Article | Year |
|---|---|
Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
Topics: Anti-Infective Agents; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mutation; Mycobacterium leprae | 2008 |
Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.
Topics: Aminoglycosides; Anti-Bacterial Agents; Carbenicillin; Ceftazidime; Ciprofloxacin; Drug Resistance, Bacterial; Drug Synergism; Humans; Microbial Sensitivity Tests; Novobiocin; Ofloxacin; Piperacillin; Polyethyleneimine; Pseudomonas aeruginosa; Pseudomonas Infections; Rifampin; Ticarcillin; Tobramycin | 2008 |
Functional cloning and characterization of the multidrug efflux pumps NorM from Neisseria gonorrhoeae and YdhE from Escherichia coli.
Topics: Anti-Bacterial Agents; Antiporters; ATP-Binding Cassette Transporters; Bacterial Proteins; Cloning, Molecular; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Proteins; Ethidium; Fluorescence Polarization; Microbial Sensitivity Tests; Neisseria gonorrhoeae; Norfloxacin | 2008 |
Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azithromycin; Bacterial Outer Membrane Proteins; Down-Regulation; Humans; Macrolides; Membrane Transport Proteins; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Quorum Sensing | 2008 |
Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
Topics: Anti-Bacterial Agents; Blood Proteins; Protein Binding; Surface Plasmon Resonance | 2009 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Benzofurans; Cell Line; DNA Gyrase; Dose-Response Relationship, Drug; Drug Design; Mice; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2014 |
An efficient synthesis and biological screening of benzofuran and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis DNA GyrB inhibition.
Topics: Animals; Antitubercular Agents; Benzofurans; Benzothiazoles; Cell Line; DNA Gyrase; Dose-Response Relationship, Drug; Humans; Macrophages; Mice; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Mycobacterium tuberculosis; Piperazines; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2014 |
Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain.
Topics: Antitubercular Agents; DNA Gyrase; Drug Discovery; Humans; Mycobacterium smegmatis; Mycobacterium tuberculosis | 2015 |
Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors.
Topics: Adenosine Triphosphatases; Antitubercular Agents; DNA Gyrase; Drug Discovery; Engineering; Microbial Sensitivity Tests; Models, Molecular; Mycobacterium tuberculosis; Protein Conformation | 2016 |
4-Quinolone interactions with gyrase subunit B inhibitors.
Topics: Aminocoumarins; Anti-Infective Agents; Coumarins; Dose-Response Relationship, Drug; Drug Interactions; Microbial Sensitivity Tests; Novobiocin; Ofloxacin; Staphylococcus aureus; Topoisomerase II Inhibitors | 1991 |
Mechanism of quinolone mutagenicity in bacteria.
Topics: Anti-Infective Agents; Blotting, Southern; Ciprofloxacin; DNA Topoisomerases, Type II; Enrofloxacin; Escherichia coli; Fleroxacin; Fluoroquinolones; Genes, Bacterial; Mutation; Novobiocin; Ofloxacin; Oxolinic Acid; Quinolones; Salmonella | 1991 |
Activity of fluoroquinolone antibiotics against Plasmodium falciparum in vitro.
Topics: Aminocoumarins; Animals; Anti-Infective Agents; Chloroquine; Ciprofloxacin; Coumarins; Drug Interactions; Drug Resistance; Enoxacin; Fluoroquinolones; Nalidixic Acid; Norfloxacin; Novobiocin; Ofloxacin; Oxolinic Acid; Pefloxacin; Plasmodium falciparum; Tetracycline; Topoisomerase II Inhibitors | 1988 |
Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts.
Topics: Cell Division; Cell Line; Ciprofloxacin; DNA Polymerase II; DNA Topoisomerases, Type I; DNA, Bacterial; Electrophoresis, Agar Gel; Humans; Lymphocytes; Novobiocin; Ofloxacin; Oxazines; Quinolines; Spheroplasts; Thymus Gland | 1986 |
In vitro activity of novobiocin against multiresistant strains of Enterococcus faecium.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Interactions; Drug Resistance, Microbial; Enterococcus faecium; Novobiocin; Ofloxacin | 1993 |
Antagonism between bactericidal activities of 4-quinolones and coumarins gives insight into 4-quinolone killing mechanisms.
Topics: Aminocoumarins; Anti-Infective Agents; Ciprofloxacin; Coumarins; DNA Topoisomerases, Type II; Escherichia coli; Genes, Bacterial; Microbial Sensitivity Tests; Mutation; Nalidixic Acid; Norfloxacin; Novobiocin; Ofloxacin; Rifampin | 1994 |
Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; DNA Topoisomerase IV; DNA Topoisomerases, Type II; DNA, Bacterial; Escherichia coli; Fluoroquinolones; Novobiocin; Ofloxacin; Quinolones; Staphylococcus aureus; Substrate Specificity; Topoisomerase II Inhibitors | 1996 |
Reversal of resistance in bacteria underlies synergistic effect of essential oils with conventional antibiotics.
Topics: Acinetobacter baumannii; Amoxicillin; Animals; Anti-Infective Agents; Bacteria; beta-Lactamases; Bicyclic Monoterpenes; Cell Line; Cell Proliferation; Cell Survival; Cyclohexenes; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Synergism; Escherichia coli; Gas Chromatography-Mass Spectrometry; Humans; Keratinocytes; Limonene; Methicillin-Resistant Staphylococcus aureus; Mice; Microbial Sensitivity Tests; Monoterpenes; Novobiocin; Ofloxacin; Oils, Volatile; Oxacillin; Piperacillin; Plant Extracts; Plant Oils; Sesquiterpenes, Eudesmane; Spleen; Terpenes; Tetracycline; Time Factors | 2017 |